Association of SGLT2 Inhibitor With Stroke in Type 2 Diabetes With Diabetic Retinopathy: A Multicenter Electronic Health Record Data Study

Documenti analoghi

• Downstream Treatment Burden and Health‐Care Utilization Following Initiation of GLP ‐1 Receptor Agonists or SGLT2 Inhibitors in Type 2 Diabetes
  di: Yazan Alhamdan, et al.
  Pubblicazione: (2026)
• Comparison of SGLT2 Inhibitors for New‐Onset Proteinuria Risk in Patients With Type 2 Diabetes and Preserved Kidney Function
  di: Hiroki Nobayashi, et al.
  Pubblicazione: (2026)
• Cardiovascular Outcomes With SGLT‐2 Inhibitors in Patients With Type 2 Diabetes and Obstructive Sleep Apnoea: A Real‐World Analysis
  di: Reuben L. Odai, et al.
  Pubblicazione: (2026)
• Adding Finerenone to SGLT2 Inhibitors and Long‐Term Kidney Outcomes in Diabetic Kidney Disease
  di: Masaru Matsui, et al.
  Pubblicazione: (2026)
• Interrelationship Between Baseline HbA1c , SGLT ‐2 Inhibitor Use and Risk of Diabetic Ketoacidosis in Adults With Type 2 Diabetes: A Systematic Review and Meta‐Analysis
  di: Samuel Seidu, et al.
  Pubblicazione: (2026)